Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
Cognition Therapeutics (NASDAQ: CGTX) released the eighth episode of its Conversations video podcast titled “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode explores how beta amyloid (Aβ) oligomers lead to synaptic dysfunction and cognitive decline. The podcast discusses recent research showing Aβ oligomers binding to synapses in Alzheimer's patients and how CT1812 can reverse this binding and reduce toxicity. Highlights include the use of quantitative EEG as a biomarker in the Phase 2 ‘SEQUEL’ study, which showed improvements in synaptic function and brain connectivity after four weeks of CT1812 treatment. Dr. Hamby presented proteomic analysis results demonstrating CT1812's positive effects on proteins and pathways linked to Alzheimer's. The discussion was moderated by Dr. Anthony Caggiano, featuring Dr. Mary Hamby, Dr. Everard Vijverberg, and Dr. Tara Spires-Jones.
- CT1812 shows potential in improving synaptic function and brain connectivity.
- Phase 2 ‘SEQUEL’ study indicated positive trends over four weeks of treatment.
- Research shows CT1812 reverses binding of Aβ oligomers, reducing synaptotoxicity.
- Proteomic analysis demonstrates CT1812's impact on Alzheimer's-related proteins and pathways.
- Quantitative EEG used as a real-time biomarker provides measurable data on synaptic function.
- The podcast does not constitute medical advice, diagnosis, or treatment.
- Results of the 'SEQUEL' study are preliminary and require further validation.
- The effectiveness of CT1812 over longer treatment periods remains unproven.
PURCHASE, N.Y., May 21, 2024 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing drugs that treat neurodegenerative disorders, has released its eighth Conversations video podcast episode: “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease.” This episode reviews how beta amyloid (Aβ) oligomers cause synaptic dysfunction, which is correlated with cognitive decline.
This conversation features a discussion of newly published research showing that Aβ oligomers bind to synapses in brain tissue of Alzheimer’s patients and how CT1812 acts to reverse their binding and reduce synaptotoxicity. Additionally, the panelists discuss using quantitative electroencephalography (EEG) as a real-time biomarker of synaptic function. In the Phase 2 ‘SEQUEL’ study of CT1812 in mild-to-moderate Alzheimer’s disease, four weeks of treatment was associated with trends to improvement in synaptic function and brain connectivity. Finally, Dr. Hamby summarized results of proteomic analysis demonstrating the impact of CT1812 treatment on proteins and pathways altered in Alzheimer’s disease, namely, synapse, amyloid beta processing and neuroinflammation.
Anthony Caggiano, M.D., Ph.D. CMO and head of R&D for Cognition Therapeutics moderates the discussion joined by VP of research, Mary Hamby, Ph.D. and two leading experts:
- Everard (Jort) Vijverberg, MD, PhD, Staff Neurologist and CNS Trial Specialist at the Amsterdam Alzheimer Center at Amsterdam Neuroscience
- Tara Spires Jones, DPhil, Personal Chair of Neurodegeneration and Deputy Director of the University of Edinburgh’s Centre for Discovery Brain Sciences
Listen to episode eight, “Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease” on the Conversations tab of the Cognition website.
Health Care Disclaimer
Our podcast series does not constitute the practice of medical advice, diagnosis or treatment. Always talk to your health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately.
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system and retina. We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). We believe CT1812 and our pipeline of σ-2 receptor modulators can regulate pathways that are impaired in these diseases. We believe that targeting the σ-2 receptor with CT1812 represents a mechanism functionally distinct from other current approaches in clinical development for the treatment of degenerative diseases. More about Cognition Therapeutics and its pipeline can be found at https://cogrx.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our product candidates, including CT1812, and any expected or implied benefits or results, including that initial clinical results observed with respect to CT1812 will be replicated in later trials and our clinical development plans, including statements regarding our clinical studies of CT1812 and any analyses of the results therefrom, are forward-looking statements. These statements, including statements relating to the timing and expected results of our clinical trials, involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: competition; our ability to secure new (and retain existing) grant funding; our ability to grow and manage growth, maintain relationships with suppliers and retain our management and key employees; our ability to successfully advance our current and future product candidates through development activities, preclinical studies and clinical trials and costs related thereto; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; the timing, scope and likelihood of regulatory filings and approvals, including regulatory approval of our product candidates; changes in applicable laws or regulations; the possibility that the we may be adversely affected by other economic, business or competitive factors, including ongoing economic uncertainty; our estimates of expenses and profitability; the evolution of the markets in which we compete; our ability to implement our strategic initiatives and continue to innovate our existing products; our ability to defend our intellectual property; impacts of ongoing global and regional conflicts; the impact of the COVID-19 pandemic on our business, supply chain and labor force; and the risks and uncertainties described more fully in the “Risk Factors” section of our annual and quarterly reports filed with the Securities & Exchange Commission and are available at www.sec.gov. These risks are not exhaustive and we face both known and unknown risks. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Casey McDonald (media) Tiberend Strategic Advisors, Inc. cmcdonald@tiberend.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
FAQ
What is the focus of Cognition Therapeutics' latest podcast episode?
What is CT1812, as discussed in Cognition Therapeutics' podcast?
How does CT1812 impact synaptic function according to the SEQUEL study?
What biomarker is used in the study to measure synaptic function?
What were the findings of the proteomic analysis presented in the podcast?
Who are the experts featured in the Cognition Therapeutics podcast?
